Analyst Scanner on Medical Laboratories and Research Equities -- Thermo Fisher Scientific, Quest Diagnostics, Exact Sciences, VWR Corp., and Bio-Reference Laboratories

Jul 21, 2015, 09:05 ET from www.equityresearchinstitute.com

NEW YORK, July 21, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Thermo Fisher Scientific Inc. (NYSE: TMO), Quest Diagnostics Inc. (NYSE: DGX), Exact Sciences Corporation (NASDAQ: EXAS), VWR Corporation (NASDAQ: VWR), and Bio-Reference Laboratories Inc. (NASDAQ: BRLI). Free research report on Thermo Fisher Scientific can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=TMO On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

Thermo Fisher Scientific Inc.'s stock edged 0.31% higher, to close the day at $136.17. The stock recorded a trading volume of 1.05 million shares, below its three months average volume of 1.65 million shares. Over the last one month and over the past three months, Thermo Fisher Scientific Inc.'s shares have gained 5.00% and 1.71%, respectively. Furthermore, the stock has advanced 8.94% since the start of this year. The company's shares are trading 4.33% above their 50-day moving average and 7.23% above their 200-day moving average. Additionally, Thermo Fisher Scientific Inc. traded at a PE ratio of 31.59 and has a Relative Strength Index (RSI) of 62.48. Sign up and read the free notes on TMO at:

https://www.EquityResearchInstitute.com/reports?keyword=TMO

On Monday, shares in Quest Diagnostics Inc. recorded a trading volume of 0.78 million shares, lower than their three months average volume of 1.53 million shares. The stock ended the day 0.23% lower at $73.09. Shares of the company traded at a PE ratio of 21.06. Although, Quest Diagnostics Inc.'s stock has lost 3.51% in the previous three months, it has advanced 0.85% in the last one month and 10.65% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 0.41% and 5.99%, respectively. Furthermore, shares of Quest Diagnostics Inc. have an RSI of 52.25. The complimentary notes on DGX can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=DGX

Exact Sciences Corp.'s stock lost 2.10%, to close Monday's session at $27.03. The stock recorded a trading volume of 1.78 million shares, above its three months average volume of 1.46 million shares. Over the last one month and since the start of this year, Exact Sciences Corp.'s shares have lost 3.88% and 1.49%, respectively. However, the stock has gained 17.57% in the previous three months. The company is trading 7.62% above its 200-day moving average.  Furthermore, Exact Sciences Corp.'s stock has an RSI of 43.42. Register for free on Equity Research Institute and access the latest research on EXAS at:

https://www.EquityResearchInstitute.com/reports?keyword=EXAS

VWR Corp.'s stock finished Monday's session 0.57% higher at $26.30. A total of 0.34 million shares were traded, which was below its three months average volume of 0.62 million shares. Over the last one month and since the beginning of 2015, VWR Corp.'s shares have gained 0.77% and 1.66%, respectively. However, the stock has lost 4.50% in the previous three months. The company's shares are trading above their 200-day moving average by 4.36%. VWR Corp.'s stock traded at a PE ratio of 18.26 and has an RSI of 49.00. The complete research on VWR is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=VWR

On Monday, shares in Bio-Reference Laboratories Inc. ended the session 1.45% lower at $44.31. The stock reported a trading volume of 0.40 million shares, below its three months average volume of 0.59 million shares. Shares of the company traded at a PE ratio of 24.35. Bio-Reference Laboratories Inc.'s shares have surged 11.11% in the last one month, 27.07% in the previous three months and 37.91% on YTD basis. The company is trading 15.53% above its 50-day moving average and 32.33% above its 200-day moving average. Moreover, shares of Bio-Reference Laboratories Inc. have an RSI of 67.01. Free in-depth research on BRLI is available at:

https://www.EquityResearchInstitute.com/reports?keyword=BRLI

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com